Posted: September 14, 2007

Research And Markets Has Announced The Addition Of Nanoparticle Drug Delivery Market Report To Their Offering

(Nanowerk News) Research and Markets ( has announced the addition of Nanoparticle Drug Delivery Market Report to their offering.
This report will give Pharma investors a comprehensive understanding on the impact of nanotechnologies on the pharmaceutical market and companies, which include companies that are producing nanomaterials/technologies to enable better drug delivery compounds (drug delivery company) and companies that are using nano-enabled formulations to enhance drug delivery (drug formulation company).
This report will provide an in-depth discussion on recent developments of nanoparticle enabled drug delivery systems (DDS) and future opportunities. It is tailored for investors who plan to invest in the pharmaceutical industry with an eye towards how nanoparticle drug delivery technology will impact the economics of the pharmaceutical market.
The information includes business summaries, technology core competencies, how nanoparticle adds value for investors in drug delivery companies, commercialization strategies, intellectual property and available markets.
There are 58 case studies on nanoparticle DDS listed according to 3 categories:
-Delivery Method/Routes of administration
The report provides a nanotechnology model based on primary research quantifying the impact and diffusion of nanotechnologies by industry sector over time. The model takes into account global R&D spending on nanotechnologies and assumes a median seven year time lag between the start of a funding program and a commercially useful output, industry R&D growth rates, global GDP growth predictions and the rate of penetration of nanotechnologies based on primary research to develop the rate of diffusion by industry sector.
Source: Research and Markets
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: